Display options
Cite
Puranik R, Bao S, Bonin AM, et al. A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. Cell Biosci. 2016;6:9doi: 10.1186/s13578-016-0076-8.
Puranik, R., Bao, S., Bonin, A. M., Kaur, R., Weder, J. E., Casbolt, L., Hambley, T. W., Lay, P. A., Barter, P. J., & Rye, K. A. (2016). A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. Cell & bioscience, 69. https://doi.org/10.1186/s13578-016-0076-8
Puranik, Rajesh, et al. "A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo." Cell & bioscience vol. 6 (2016): 9. doi: https://doi.org/10.1186/s13578-016-0076-8
Puranik R, Bao S, Bonin AM, Kaur R, Weder JE, Casbolt L, Hambley TW, Lay PA, Barter PJ, Rye KA. A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. Cell Biosci. 2016 Feb 06;6:9. doi: 10.1186/s13578-016-0076-8. eCollection 2016. PMID: 26855766; PMCID: PMC4744413.
Copy Download .nbib Format: NLM
Share it on

Cell Biosci. 2016 Feb 06;6:9. doi: 10.1186/s13578-016-0076-8. eCollection 2016.

A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo.

Cell & bioscience

Rajesh Puranik, Shisan Bao, Antonio M Bonin, Ravinder Kaur, Jane E Weder, Llewellyn Casbolt, Trevor W Hambley, Peter A Lay, Philip J Barter, Kerry-Anne Rye

Affiliations

  1. The Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Department of Cardiology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050 Australia.
  2. The Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Discipline of Pathology, D17, The School of Medical Sciences and Bosch Institute, The University of Sydney, Sydney, NSW 2006 Australia.
  3. The School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
  4. Casbolt & Associates Pty Ltd, Sydney, Australia.
  5. The Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia.
  6. The Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Lipid Research Group, Centre for Vascular Research, The University of New South Wales, Sydney, NSW 2052 Australia.

PMID: 26855766 PMCID: PMC4744413 DOI: 10.1186/s13578-016-0076-8

Abstract

BACKGROUND: The ability of Zn(II) and Cu(II) metal complexes of non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit acute arterial inflammation in vivo has been studied.

RESULTS: When acute vascular inflammation was induced in normocholesterolemic New Zealand White rabbits by inserting a non-occlusive silastic collar around the common carotid artery, a single oral dose of Cu(II)-indomethacin (Cu(II)Indo, 3 mg/kg) administered by laparotomy achieved a 67 % (8.2 ± 1.7 vs. 2.7 ± 0.4 image units, p < 0.05) reduction in endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) but did not inhibit endothelial intercellular adhesion molecule (ICAM-1) expression significantly. Treatment with Cu(II)-acemetacin (Cu(II)ACM, 3 mg/kg) led to a profound 88 % (8.2 ± 1.7 vs. 1.0 ± 0.5 image units, p < 0.01) reduction in endothelial VCAM-1 expression but did not inhibit ICAM-1 expression, while treatment with Zn(II)-acemetacin (Zn(II)ACM, 3 mg/kg) led to an 84 % (19.3 ± 1.0 vs. 3.1 ± 1.2 image units, p < 0.01) reduction in endothelial ICAM-1 expression and did not inhibit VCAM-1 expression. No adverse gastric, hepatic or renal effects were observed in treated animals.

CONCLUSION: These findings provide the "proof of concept" that this novel class of drug, where there is complexation of NSAIDs with metal ions, has substantial anti-inflammatory effects in an animal model of acute vascular inflammation with the possibility of low rates of adverse effects.

Keywords: Copper(II) ACM; Copper(II) indomethacin; Indomethacin; NSAIDs; Zinc(II) ACM

References

  1. Clin Chem. 1979 Feb;25(2):325-7 - PubMed
  2. Atherosclerosis. 2008 Jan;196(1):240-7 - PubMed
  3. J Inorg Biochem. 2004 Nov;98(11):1734-49 - PubMed
  4. Dtsch Med Wochenschr. 1952 Jul 4;77(27-28):870-2 - PubMed
  5. J Rheumatol. 2005 Nov;32(11):2218-24 - PubMed
  6. Br J Pharmacol. 2008 Nov;155(6):857-64 - PubMed
  7. Am J Med. 2001 Feb 19;110 Suppl 3A:13S-9S - PubMed
  8. Prog Med Chem. 1989;26:437-568 - PubMed
  9. Inorg Chem. 1997 Mar 12;36(6):1168-1175 - PubMed
  10. Chem Res Toxicol. 2003 Jan;16(1):28-37 - PubMed
  11. Int J Cardiol. 2013 Oct 12;168(5):4839-41 - PubMed
  12. J Investig Med. 2009 Aug;57(6):695-702 - PubMed
  13. Circulation. 2007 Mar 27;115(12):1634-42 - PubMed
  14. Curr Pharm Des. 2005;11(14):1779-93 - PubMed
  15. BMC Musculoskelet Disord. 2007 Aug 03;8:73 - PubMed
  16. Br J Clin Pharmacol. 1991 May;31(5):543-5 - PubMed
  17. Clin Biochem. 1994 Aug;27(4):310-5 - PubMed
  18. J Am Coll Cardiol. 2008 Oct 28;52(18):1502-17 - PubMed
  19. J Am Coll Cardiol. 2002 Apr 3;39(7):1133-8 - PubMed

Publication Types